VA
VTGN icon

Verdad Advisers’s VistaGen Therapeutics VTGN Stock Holding History

Verdad Advisers’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$106K Buy
+184,938
New +$112K 0.12% 154

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Verdad Advisers's VTGN Position: Q1 2026 in Review

Verdad Advisers opened a new position in VistaGen Therapeutics (VTGN) in Q1 2026: 184,938 shares worth $106K. The stake represents 0.12% of the portfolio and ranks #154 among its holdings.

56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Verdad Advisers held 184,938 shares of VistaGen Therapeutics worth $106K as of Q1 2026.
  • VistaGen Therapeutics was a new Verdad Advisers position in Q1 2026.
  • VistaGen Therapeutics made up 0.12% of Verdad Advisers's portfolio in Q1 2026, its #154 holding.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.